Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (RARE) Stock Overview

Explore Ultragenyx Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.

RARE●NASDAQ
HealthcareBiotechnology
$24.91
$1.13(4.34%)
U.S. Market opens in 38h 31m

Ultragenyx Pharmaceutical Inc. (RARE)

Meyka AI Score

Z

Key Financials

Market Cap2.5B
P/E Ratio-4.08
EPS (TTM)$-6.11
ROE15.67%
Fundamental Analysis

AI Price Forecasts

1 Month$29.27
3 Months$30.63
1 Year Target$17.98

RARE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Ultragenyx Pharmaceutical Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RARE on the NASDAQ shows an RSI of 34.29, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $17.98 for the NASDAQ listing.

Key metrics behind Ultragenyx Pharmaceutical Inc.'s NASDAQ-traded stock include a P/E ratio of -4.08 and a market capitalization of 2.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RARE on the NASDAQ.

Price Performance (NASDAQ: RARE)

1-Day Change
-4.34%
5-Day Change
-8.82%
1-Month Change
-25.40%
3-Month Change
0.89%
6-Month Change
3.49%
Year-to-Date (YTD) Change
8.30%
1-Year Change
-8.82%
3-Year Change
-42.23%
5-Year Change
-69.19%
All-Time (Max) Change
-41.04%

Contact Information

https://www.ultragenyx.com
415 483 8800
60 Leveroni Court, Novato, CA, 94949

Company Facts

13,710 Employees
IPO DateJan 31, 2014
CountryUS
Actively Trading

Frequently Asked Questions